Navigation Links
NPS Pharmaceuticals Announces Senior Management Changes
Date:2/26/2008

late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and parathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism (parathyroid hormone 1-84 [rDNA origin] injection). NPS has also completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84 [rDNA origin] injection). NPS complements its internal programs with strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and Nycomed. Additional information is available at http://www.npsp.com.

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to NPS's business include, but are not limited to, the risk of successfully advancing its preclinical and clinical pipeline and gaining marketing approvals for its product candidates, as well as other factors expressed in NPS's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
7. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
8. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
9. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
10. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... MUNDELEIN, Ill. , May 23, 2013 ... company providing value-added ingredients to a variety of industries, ... participated in a panel discussion at this year,s National ... May 20-21, 2013, on behalf of the Research Chefs ... Development for Restaurants: The Good, the Bad and the ...
(Date:5/23/2013)...  Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that ... at two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ... Second Annual Marcum LLP Microcap Conference on Thursday, May ... York City.  The presentation is scheduled to begin at ...
(Date:5/23/2013)... 23, 2013 African Ancestry ... for people of African descent, today announced new ... For people of all races, myDNAmix determines various ... distinct populations: Indigenous Americas (Native American), East Asia, ... , Originally launched in late 2011, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Ralph Huber, President ... their emergency management products and emergency survival kits ... This announcement was made at the quarterly executive board meeting ... a moment of silence for the Oklahoma tornado victims and ... the quality of their emergency kits is paramount. “When ...
Breaking Biology Technology:Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits 2
... (OTCQB: ILIU) today issued financial and operational results for ... December 31, 2010. "We made good ... with Stanford University, data from a clinical study was ... genetics has in improving weight loss.  Our Inherent Health ...
... FRANCISCO, March 21, 2011 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) agonists and antagonists ... diseases, announced today the presentation of positive clinical ... VTX-1463 for the treatment of allergic rhinitis. The ...
... SAN CARLOS, Calif., March 21, 2011 WaferGen ... ), a leading developer of state-of-the-art genomic analysis ... innovative genomic samples preparation, today announced they will ... gene expression profiling and target enrichment to enable ...
Cached Biology Technology:Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 2Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 3Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 4Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 5Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 6Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 7VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... genetic engineering drastically reduces the time and effort ... workhorses of biotechnology, scientists are reporting. Published in ... method paves the way for more rapid development ... and other activities. , Keith Shearwin and colleagues ... the genetic material DNA into a bacterium,s genome ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... Biochemist Glenn King is searching for an alternative to ... one the world's most efficient insect predators -- spiders. ... large Australian spider with a bite that is deadly ... of venom for King's research. The spider "cooperates" by ...
... B cell chronic lymphocytic leukemia (B-CLL),is the most ... the,progressive accumulation of mature B lymphocytes in the ... that in the early stages,of disease, B-CLL is ... signals that trigger normal B cell death (apoptosis). ...
... rapid advancement of biomedical science and the development ... types of information from biomedical text has become ... quite useful for interpreting large amounts of high-throughput ... information related to gene functions from text has ...
Cached Biology News:Spider Venom Could Yield Eco-Friendly Insecticides 2Spider Venom Could Yield Eco-Friendly Insecticides 3
... Vibratome Company has joined forces with the ... Vibratome 800 Tissue Chopper. This tissue sectioning ... of tissue for metabolic experiments and to ... specimens available at biopsy or from small ...
... Custom Peptide Services offer a full ... your research needs. Services include: Peptide ... Peptide synthesis, purified product (70-95% ... (acetylation, amidation, biotinylation, fluorescein, myristylation, phosphorylation, and ...
... an integrated confocal laser scanner designed to ... your specific application. GeneFocus can recommend a ... system to your specifications. The Open ... been modularized and built onto an optical ...
...
Biology Products: